BioAge says early data suggest ‘best-in-class’ potential for inflammation drug
BioPharma Dive
The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting NLRP3, an inflammasome linked to a variety of health conditions.
pharminent
April 21, 2026 (Last updated: April 21, 2026)
BioPharma Dive
The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting NLRP3, an inflammasome linked to a variety of health conditions.